Ocular Genetic Diagnostic Market Growth Forecast With Analysis Of Industry Progress Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Increase In Market Value Is Predicted For The Ocular Genetic Diagnostic Market During The 2026–2030 Period?

The ocular genetic diagnostic market has experienced substantial expansion in recent years. Its value is projected to climb from $1.07 billion in 2025 to $1.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.5%. Historically, this market’s expansion can be attributed to factors such as the increasing prevalence of inherited ocular conditions, advancements in sequencing technologies, the rise of specialized ophthalmic clinics, greater awareness of genetic eye disorders, and the extended reach of diagnostic laboratory capabilities.

The ocular genetic diagnostic market size is projected to experience robust expansion over the next few years. It is predicted to reach $1.67 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.3%. This growth during the forecast period can be attributed to several factors, including an increasing demand for personalized ophthalmic treatments, the rising adoption of whole genome sequencing, the expansion of preventive genetic screening programs, the growing integration of AI in genetic interpretation, and increasing investments in precision ophthalmology. Significant trends expected in this period include the increasing uptake of comprehensive genetic screening panels, the growing utilization of next-generation sequencing in ophthalmology, an expansion of early diagnosis options for inherited eye disorders, the rising incorporation of genetic counseling services, and an enhanced focus on precision eye care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28283&type=smp

What Important Drivers Are Powering The Ocular Genetic Diagnostic Market Growth?

The anticipated growth of the ocular genetic diagnostic market is linked to the rising occurrence of eye diseases. These diverse medical conditions affect the eye’s structure or function and can lead to vision impairment or blindness if left untreated. A significant contributor to the increase in eye diseases is the elevated screen time and digital device usage, which results in issues such as eye strain and dry eye. Ocular genetic diagnostics provides benefits for eye diseases by facilitating the early detection of inherited genetic factors, offering clearer insights into disease causes, and assisting in more precise diagnosis and management. For instance, in February 2025, a survey by the American Foundation for the Blind, a US-based organization focusing on individuals with vision loss, reported that 51.9 million American adults aged 18 and older experienced some level of vision difficulty. Among these, 3.7 million had significant trouble seeing even with glasses, and 307,000 were completely blind. The remaining 47.9 million indicated mild vision difficulties despite wearing glasses. This demonstrates how the increasing prevalence of eye diseases is fueling the expansion of the ocular genetic diagnostic market.

How Are Different Segment Groups Identified Within The Ocular Genetic Diagnostic Market?

The ocular genetic diagnostic market covered in this report is segmented –

1) By Test Type: Single Gene Testing, Panel Testing, Whole Exome Sequencing, Whole Genome Sequencing

2) By Technology Type: Sequencing Technology, Polymerase Chain Reaction (PCR), Microarray Technology, Next-Generation Sequencing (NGS)

3) By Application: Retinal Disorders, Cataract Diagnosis, Inherited Ocular Disorders, Age-Related Macular Degeneration

4) By End-User: Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Single Gene Testing: Retinoblastoma Gene Testing (RB1), RPE65 Gene Mutation Testing, MYOC Gene Testing (Glaucoma), OPA1 Gene Testing (Optic Atrophy), BEST1 Gene Testing (Best Disease)

2) By Panel Testing: Inherited Retinal Disease (IRD) Panels, Glaucoma Genetic Panels, Macular Dystrophy Panels, Optic Neuropathy Panels, Syndromic Ocular Disorder Panels

3) By Whole Exome Sequencing (WES): Trio Exome Sequencing, Diagnostic Exome Sequencing, Exome Reanalysis Services, Rapid Exome Testing, Prenatal Exome Sequencing

4) By Whole Genome Sequencing (WGS): Clinical Whole Genome Sequencing, Rapid Whole Genome Sequencing, Pediatric Genome Sequencing, Prenatal Whole Genome Sequencing, Ultra-Rare Eye Disease Genome Sequencing

Which Trends Are Expected To Shape The Ocular Genetic Diagnostic Market?

Leading organizations in the occupational therapy market are innovating with technologies, including AI-driven physical rehabilitation solutions, to secure a competitive advantage. An AI-powered physical rehabilitation solution represents a technological advancement that harnesses artificial intelligence to significantly improve and redefine the domain of physical therapy and rehabilitation. For example, in June 2024, Sword Health, a Portugal-based healthcare provider, unveiled an AI solution named Phoenix, intended to elevate virtual physical therapy sessions. This inventive tool allows patients to engage in dialogue with Phoenix, receiving immediate direction and feedback during their treatment. Patients can communicate their sentiments and advancement, with the AI consequently modifying the session’s challenge level and duration. Phoenix also evaluates patient movements, offering instant feedback while condensing performance metrics for review by Sword’s human clinicians, who confirm the safety and suitability of the exercises.

Which Firms Are Competing In The Ocular Genetic Diagnostic Market?

Major companies operating in the ocular genetic diagnostic market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Illumina Inc., The Children’s Hospital of Philadelphia, University of Iowa Hospitals and Clinics, PerkinElmer Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., ARUP Laboratories Inc., Invitae Corporation, Spark Therapeutics Inc., GeneDx LLC, Blueprint Genetics Oy, Medgenome Labs Inc., Centogene NV, PreventionGenetics LLC, Molecular Vision Laboratory LLC, Casey Eye Institute, Moorfields Eye Hospital & UCL Institute of Ophthalmology.

Access The Complete Ocular Genetic Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/ocular-genetic-diagnostic-global-market-report

Which Region Accounts For The Highest Share Of The Ocular Genetic Diagnostic Market?

North America was the largest region in the ocular genetic diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ocular genetic diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Ocular Genetic Diagnostic Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=28283&type=smp

Browse Through More Reports Similar to the Global Ocular Genetic Diagnostic Market 2026, By The Business Research Company

Occupational Health Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/occupational-health-global-market-report

Occupational Medicines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/occupational-medicines-global-market-report

Physical Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/physical-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795